PharmaRoth Labs, Inc. (ROTH) Stock Price & Analysis

PharmaRoth Labs, Inc. (ROTH) Healthcare & Pipeline Overview

PharmaRoth Labs, Inc. is a nutraceutical company specializing in herbal-based treatments for type-2 diabetes, primarily through its Sucanon product. Operating globally from its Las Vegas headquarters, the company faces competition in the biotechnology sector while addressing a significant market need.

What Is the Investment Thesis for ROTH?

PharmaRoth Labs, Inc. presents a focused investment opportunity within the nutraceutical market, specifically targeting type-2 diabetes with its Sucanon product. The company's gross margin of 40.2% indicates potential profitability, but its negative profit margin of -278.6% raises concerns about operational efficiency and cost management. Key value drivers include expanding Sucanon's market share and achieving regulatory approvals in new geographic regions. Growth catalysts involve strategic partnerships and further clinical validation of Sucanon's efficacy. Potential risks include competition from established pharmaceutical companies and the evolving regulatory landscape for nutraceuticals. Investors should closely monitor the company's ability to improve its profit margins and demonstrate sustained revenue growth.

Based on FMP financials and quantitative analysis

ROTH Key Highlights

PharmaRoth Labs, Inc. focuses on the nutraceutical market, specifically targeting type-2 diabetes with its Sucanon product.

• The company's gross margin stands at 40.2%, indicating potential profitability from its core product.
• PharmaRoth Labs, Inc. rebranded from Fero Industries Inc. in March 2013, signaling a strategic shift towards the nutraceutical market.
• The company's negative profit margin of -278.6% raises concerns about operational efficiency and cost management.
• PharmaRoth Labs, Inc. has a beta of 0.38, suggesting lower volatility compared to the overall market.

Who Are ROTH's Competitors?

ROTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ROTH's Key Strengths?

Focus on herbal-based nutraceutical treatments.

• Proprietary formulation of Sucanon.
• Established presence in certain markets.
• Gross margin of 40.2%.

What Are ROTH's Weaknesses?

Negative profit margin of -278.6%.

• Limited product portfolio.
• Dependence on Sucanon for revenue.
• Small market capitalization.

What Are the Key Risks for ROTH?

Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.

• Competition from established pharmaceutical companies and other nutraceutical firms.
• Evolving regulatory landscape for nutraceutical products.
• Adverse effects of Sucanon.
• Negative profit margin and operational inefficiencies.

What Are ROTH's Competitive Advantages?

• Proprietary formulation of Sucanon, providing a unique herbal-based treatment for type-2 diabetes.
• Established brand recognition and customer loyalty in certain markets.
• Strategic partnerships with distributors and healthcare providers.

What Does ROTH Do?

PharmaRoth Labs, Inc., established in 2000 and headquartered in Las Vegas, Nevada, operates as a nutraceutical company with a focus on developing, marketing, and distributing herbal-based treatments. The company's flagship product is Sucanon, a nutraceutical designed for individuals with type-2 diabetes. Originally known as Fero Industries Inc., the company rebranded to PharmaRoth Labs, Inc. in March 2013, signaling a strategic shift towards the nutraceutical market. PharmaRoth Labs aims to provide alternative treatment options for managing diabetes through natural ingredients. The company's business model involves direct marketing and distribution of Sucanon to consumers across various global markets. PharmaRoth Labs competes with both pharmaceutical companies offering traditional diabetes medications and other nutraceutical firms providing alternative treatments. The company's success hinges on the efficacy and market acceptance of Sucanon, as well as its ability to navigate the regulatory landscape for nutraceutical products in different countries. The company's focus remains on expanding its market reach and enhancing its product offerings within the nutraceutical space.

What Products and Services Does ROTH Offer?

• Develops herbal-based nutraceutical treatments.
• Focuses on producing Sucanon, a treatment for type-2 diabetes.
• Markets Sucanon to consumers worldwide.
• Distributes Sucanon through various channels.
• Conducts research and development to improve its products.
• Seeks regulatory approvals for its products in different countries.
• Engages in strategic partnerships to expand its market reach.

How Does ROTH Make Money?

• Develops and manufactures Sucanon, an herbal-based nutraceutical treatment for type-2 diabetes.
• Markets and distributes Sucanon directly to consumers and through distributors.
• Generates revenue through the sale of Sucanon in various global markets.

What Industry Does ROTH Operate In?

PharmaRoth Labs, Inc. operates within the biotechnology industry, specifically focusing on the nutraceutical segment. The global nutraceutical market is experiencing growth driven by increasing consumer awareness of preventive healthcare and natural remedies. The competitive landscape includes established pharmaceutical companies and other nutraceutical firms. PharmaRoth Labs' success depends on its ability to differentiate Sucanon through clinical validation and effective marketing strategies. The company must also navigate the regulatory complexities associated with nutraceutical products in various global markets. The market size for diabetes treatments, including nutraceuticals, is substantial and growing, presenting both opportunities and challenges for PharmaRoth Labs.

Who Are ROTH's Key Customers?

• Individuals with type-2 diabetes seeking alternative treatment options.
• Healthcare providers who recommend or prescribe nutraceutical treatments.
• Distributors and retailers who sell nutraceutical products to consumers.

PharmaRoth Labs, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Return on equity for PharmaRoth Labs, Inc. stands at 17.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.1%, showing how much profit it generates from its asset base. A current ratio of 0.35 means current liabilities exceed short-term assets, a liquidity point worth watching.

Company Profile

PharmaRoth Labs, Inc. operates in the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Luis Manuel Ornelas Lopez. ROTH has traded publicly since 2009.

ROTH Financials

ROTH Latest News

ROTH Analyst Consensus

ROTH MoonshotScore

PharmaRoth Labs, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources